Ibrexafungerp
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Candidiasis
Conditions
Vulvovaginal Candidiasis
Trial Timeline
May 1, 2022 → Aug 2, 2023
NCT ID
NCT05399641About Ibrexafungerp
Ibrexafungerp is a phase 3 stage product being developed by Scynexis for Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05399641. Target conditions include Vulvovaginal Candidiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06954493 | Phase 1 | Completed |
| NCT05668429 | Phase 1 | Completed |
| NCT05399641 | Phase 3 | Completed |
| NCT03059992 | Phase 3 | Completed |
Competing Products
10 competing products in Vulvovaginal Candidiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal | Novo Nordisk | Phase 3 | 76 |
| Fluconazole | Pfizer | Phase 3 | 76 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 82 |
| SCY-078 + Fluconazole | Scynexis | Phase 2 | 44 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 69 |
| Ibrexafungerp | Scynexis | Phase 1 | 25 |
| Estradiol + Placebo | TherapeuticsMD | Phase 3 | 69 |
| Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) | Matinas Biopharma | Phase 2 | 44 |